Cell Reports Medicine · 2023 · 39 citations · 32 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyAdverse Events Following ImmunizationMrna Vaccine TechnologyNucleic Acid VaccinesVaccinationVaccine SafetyViral VaccinesCoronavirus VaccinesMessenger Ribonucleic Acid (Mrna) Vaccine FormulationsMessenger Rna VaccinesReceptor Binding Domain VaccinesSars-cov-2 InfectionSelf-amplifying Messenger RnaSelf-amplifying Ribonucleic Acid (Rna) VaccineSelf-amplifying Rna Vaccines
VLPCOV-01 is a lipid nanoparticle-encapsulated self-amplifying RNA (saRNA) vaccine that expresses a membrane-anchored receptor-binding domain (RBD) derived from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. A phase 1 study of VLPCOV-01 is conducted (jRCT2051210164). Participants who completed two doses of the BNT162b2 mRNA vaccine previously are randomized to receive one intramuscular vaccination of 0.3, 1.0, or 3.0 μg VLPCOV-01, 30 μg BNT162b2, or placebo. No serious adverse events have been reported. VLPCOV-01 induces robust immunoglobulin G (IgG) titers against the RBD protein that are maintained up to 26 weeks in non-elderly participants, with geometric means ranging from 5,037 (95% confidence interval [CI] 1,272-19,940) at 0.3 μg to 12,873 (95% CI 937-17,686) at 3 μg compared with 3,166 (95% CI 1,619-6,191) with 30 μg BNT162b2. Neutralizing antibody titers against all variants of SARS-CoV-2 tested are induced. VLPCOV-01 is immunogenic following low-dose administration. These findings support the potential for saRNA as a vaccine platform.
32
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael et al. · New England Journal of Medicine · 2020 · 3.5K citations · Full text
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Jerald Sadoff, Glenda Gray, An Vandebosch et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text